Isembyld is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Isembyld is given by a doctor or nurse, not picked up at a pharmacy.

  1. Ask your care team or your plan what you’d pay before your visit.

Compare every option

Question
Brand nameIsembyld
Authorized genericapitegromab-mstn
Regular genericapitegromab-mstn
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Isembyld?
The original
–
–

Brand nameThe maker’s card

Scholar Rock Supports Commercial Copay Program

Savings card from Scholar Rock

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a month

Sign up on scholarrocksupports.com 

Or call 1-833-777-5444.

In the maker’s words

“to as low as $0 per month for ISEMBYLD…”

From the maker’s offer on scholarrocksupports.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Isembyld itself, from the same company, sold without the brand name, and usually for less. For now Isembyld is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Isembyld is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

ISEMBYLD is a recombinant monoclonal antibody targeting proforms of myostatin, indicated for the treatment of spinal muscular atrophy (SMA) in adults and pediatric patients 2 years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment.

Source: the FDA label for Isembyld (Scholar Rock, Inc.), September 14, 2026. Full label on DailyMed 

Good to know